{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:19:55Z","timestamp":1789849195874,"version":"4.0.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejinme.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ejim.2018.05.029","type":"journal-article","created":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T12:25:09Z","timestamp":1528806309000},"page":"57-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients"],"prefix":"10.1016","volume":"58","author":[{"given":"Ver\u00f3nica","family":"Gonz\u00e1lez-Calle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Mar\u00eda Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2018.05.029_bb0005","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2018.05.029_bb0010","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.mayocp.2012.06.014","article-title":"Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition","volume":"87","author":"Therneau","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejim.2018.05.029_bb0015","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2014.34","article-title":"Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and nutritional examination survey","volume":"28","author":"Landgren","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.ejim.2018.05.029_bb0020","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood-2010-01-262394","article-title":"Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women","volume":"116","author":"Landgren","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.05.029_bb0025","series-title":"Treatment for high-risk smoldering myeloma. The New England journal of medicine","first-page":"1762","volume":"369","author":"Kristinsson","year":"2013"},{"key":"10.1016\/j.ejim.2018.05.029_bb0030","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejim.2018.05.029_bb0035","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/ejh.12172","article-title":"Monoclonal gammopathy of undetermined significance: a new proposal of workup","volume":"91","author":"Mangiacavalli","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ejim.2018.05.029_bb0040","doi-asserted-by":"crossref","unstructured":"Go RS, Rajkumar SV. How I manage monoclonal gammopathy of undetermined significance. 2018;131:163\u201373.","DOI":"10.1182\/blood-2017-09-807560"},{"key":"10.1016\/j.ejim.2018.05.029_bb0045","doi-asserted-by":"crossref","first-page":"685","DOI":"10.4065\/84.8.685","article-title":"Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients","volume":"84","author":"Bida","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejim.2018.05.029_bb0050","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1182\/blood-2010-04-282848","article-title":"Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study","volume":"116","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.05.029_bb0055","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.71","article-title":"Factors associated with an increased risk of vertebral fracture in monoclonal gammopathies of undetermined significance","volume":"5","author":"Piot","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ejim.2018.05.029_bb0060","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nrendo.2016.54","article-title":"Dietary supplements and disease prevention - a global overview","volume":"12","author":"Rautiainen","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ejim.2018.05.029_bb0065","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.seminhematol.2010.11.002","article-title":"Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance","volume":"48","author":"Kristinsson","year":"2011","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ejim.2018.05.029_bb0070","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.thromres.2009.01.004","article-title":"The relationship between monoclonal gammopathy of undetermined significance and venous thromboembolic disease","volume":"125","author":"Cohen","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejim.2018.05.029_bb0075","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/bjh.12168","article-title":"Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients","volume":"160","author":"Za","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2018.05.029_bb0080","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/leu.2013.34","article-title":"Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients","volume":"27","author":"Roeker","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.ejim.2018.05.029_bb0085","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/1756-185X.12267","article-title":"A case series of autoimmune diseases accompanied by incidentally diagnosed monoclonal gammopathy: is there a link between the two diseases?","volume":"17","author":"Cho","year":"2014","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.ejim.2018.05.029_bb0090","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1182\/blood-2011-04-347559","article-title":"Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study","volume":"118","author":"Lindqvist","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.05.029_bb0095","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1182\/blood-2007-10-121285","article-title":"Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders","volume":"111","author":"Brown","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.05.029_bb0100","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00277-016-2859-8","article-title":"History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study","volume":"96","author":"Lindqvist","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ejim.2018.05.029_bb0105","series-title":"Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology","first-page":"332","article-title":"Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review","volume":"vol. 23","author":"McShane","year":"2014"},{"key":"10.1016\/j.ejim.2018.05.029_bb0110","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.mayocp.2017.02.003","article-title":"Monoclonal Gammopathy-associated peripheral neuropathy: diagnosis and management","volume":"92","author":"Chaudhry","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejim.2018.05.029_bb0115","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/ki.2014.408","article-title":"Diagnosis of monoclonal gammopathy of renal significance","volume":"87","author":"Bridoux","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2018.05.029_bb0120","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1182\/blood-2012-07-445304","article-title":"Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant","volume":"120","author":"Leung","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.05.029_bb0125","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.78","article-title":"Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the international myeloma working group","volume":"7","author":"Hillengass","year":"2017","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ejim.2018.05.029_bb0130","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejim.2018.05.029_bb0135","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/leu.2014.230","article-title":"The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma","volume":"28","author":"Kastritis","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.ejim.2018.05.029_bb0140","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMc1106428","article-title":"Diagnosis of smoldering multiple myeloma","volume":"365","author":"Rajkumar","year":"2011","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ejim.2018.05.029_bb0145","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/leu.2012.309","article-title":"Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease","volume":"27","author":"Kastritis","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.ejim.2018.05.029_bb0150","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2012.296","article-title":"Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma","volume":"27","author":"Larsen","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.ejim.2018.05.029_bb0155","series-title":"How Should We Treat Newly Diagnosed Multiple Myeloma Patients? ASH Education Program Book","first-page":"488","volume":"2013","author":"Mateos","year":"2013"},{"key":"10.1016\/j.ejim.2018.05.029_bb0160","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.05.029_bb0165","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.2013.51.1345","article-title":"Performance of two geriatric screening tools in older patients with cancer","volume":"32","author":"Kenis","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2018.05.029_bb0170","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cger.2015.08.012","article-title":"Monoclonal Gammopathy of undetermined significance and multiple myeloma in older adults","volume":"32","author":"Guerard","year":"2016","journal-title":"Clin Geriatr Med"},{"key":"10.1016\/j.ejim.2018.05.029_bb0175","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ejim.2018.05.029_bb0180","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","article-title":"Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study","volume":"375","author":"Dispenzieri","year":"2010","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ejim.2018.05.029_bb0185","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00277-011-1293-1","article-title":"Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany","volume":"91","author":"Eisele","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ejim.2018.05.029_bb0190","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1200\/JCO.2002.20.6.1625","article-title":"Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"20","author":"Cesana","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejim.2018.05.029_bb0195","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/leu.2008.203","article-title":"Pathogenesis and progression of monoclonal gammopathy of undetermined significance","volume":"22","author":"Blade","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.ejim.2018.05.029_bb0200","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.05.029_bb0205","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4065\/82.4.428","article-title":"Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size","volume":"82","author":"Rosinol","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejim.2018.05.029_bb0210","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1365-2141.2009.07929.x","article-title":"Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells","volume":"148","author":"Perez-Persona","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2018.05.029_bb0215","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/blood-2013-05-505487","article-title":"Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden","volume":"123","author":"Turesson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.05.029_bb0220","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"Perez-Persona","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.05.029_bb0225","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.ejim.2018.05.029_bb0230","series-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. The New England journal of medicine","first-page":"2582","volume":"356","author":"Kyle","year":"2007"},{"key":"10.1016\/j.ejim.2018.05.029_bb0235","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1038\/leu.2016.123","article-title":"Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma","volume":"30","author":"Gonz\u00e1lez-Calle","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.ejim.2018.05.029_bb0240","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/leu.2012.237","article-title":"High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma","volume":"27","author":"Bianchi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.ejim.2018.05.029_bb0245","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/leu.2016.205","article-title":"Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression","volume":"31","author":"Gonsalves","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ejim.2018.05.029_bb0250","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1046\/j.1365-2141.2003.04654.x","article-title":"Smoldering multiple myeloma: natural history and recognition of an evolving type","volume":"123","author":"Rosinol","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2018.05.029_bb0255","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/leu.2013.86","article-title":"Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma","volume":"27","author":"Rajkumar","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.ejim.2018.05.029_bb0260","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.revmed.2014.10.366","article-title":"Monoclonal gammopathies of undetermined significance do not systematically require a specialized consultation","volume":"36","author":"Fouquet","year":"2015","journal-title":"La Revue de Med. Int."},{"key":"10.1016\/j.ejim.2018.05.029_bb0265","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2018.05.029_bb0270","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","article-title":"Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial","volume":"17","author":"Mateos","year":"2016","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620518302255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620518302255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T12:21:09Z","timestamp":1720354869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620518302255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":54,"alternative-id":["S0953620518302255"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2018.05.029","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2018.05.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}